Filing Details

Accession Number:
0001415889-25-002158
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-01-28 16:04:45
Reporting Period:
2025-01-24
Accepted Time:
2025-01-28 16:04:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1802665 Harmony Biosciences Holdings Inc. HRMY () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1677141 Sandip Kapadia C/O Harmony Biosciences Holdings, Inc.
630 W Germantown Pike, Suite 215
Plymouth Meeting PA 19462
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-01-24 3,812 $0.00 3,812 No 4 M Direct
Common Stock Disposition 2025-01-24 2,037 $38.01 1,775 No 4 F Direct
Common Stock Disposition 2025-01-27 1,775 $38.05 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2025-01-24 3,812 $0.00 3,812 $0.00
Common Stock Stock Option Acquisiton 2025-01-25 66,250 $0.00 66,250 $38.01
Common Stock Restricted Stock Units Acquisiton 2025-01-25 18,900 $0.00 18,900 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,438 No 4 M Direct
66,250 2035-01-25 No 4 A Direct
18,900 No 4 A Direct
Footnotes
  1. Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.68. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
  5. The stock option vests with respect to 25% of the underlying shares on January 25, 2026, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
  6. . The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.